ArticleVaccines2022
Stakeholder Perspectives of Australia's National HPV Vaccination Program.
Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Human papillomavirus vaccine uptake and the impact of school-based health services in Switzerland: a cross-sectional study.BMJ public health · 2026Article
- Willingness to receive cross-border human papillomavirus vaccination among Chinese male university students: a cross-sectional study with statistical indirect-association analysis.Frontiers in public health · 2026Article
- Identifying barriers to human papillomavirus vaccination in China: a topic modelling analysis of social media (2018-2024).BMJ public health · 2026Article
- Human papillomavirus vaccination willingness and influencing factors among women in China: A systematic review and meta-analysis.Preventive medicine reports · 2025Review
- Article
- Designing School-Based Cancer Education for Sustained Behavioural Change.Journal of cancer education : the official journal of the American Association for Cancer Education · 2025Article
- Article
- Article
- Article
- School-based HPV vaccination program implementation in municipalities of the São Paulo State, Brazil, from 2015 to 2018.Cadernos de saude publica · 2025Article
- Beyond Averages: Unpacking Disparities in School-Based Vaccination Coverage in Eastern Sydney: An Ecological Analysis.Vaccines · 2024Article
- Knowledge and Awareness of HPV, the HPV Vaccine and Cancer-Related HPV Types among Indigenous Australians.International journal of environmental research and public health · 2024Article
- Development and validation of an HPV infection knowledge assessment scale among Aboriginal and Torres Strait Islander Peoples.Vaccine: X · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Australia has been a world leader in human papillomavirus (HPV) vaccination and was the first country to implement a fully funded national HPV vaccination program, from 2007 for girls and 2013 for boys. In 2018 the program changed from a 4-valent to 9-valent HPV vaccine and a 3-dose to 2-dose standard schedule. We assessed stakeholder perspectives on factors influencing program outcomes and impact as part of a comprehensive program evaluation. In late 2019 and early 2020, we conducted 26 interviews with 42 key stakeholder participants and received 1513 survey responses from stakeholders including general practice staff and school-based nurse immunisers. Findings included that the 2-dose schedule is better accepted by schools and students and has reduced program cost and resource requirements. However, course completion rates have not increased as much as anticipated due to the 6-12 month dosing interval and reduced opportunities for school-based catch-up vaccination. Major reported barriers to increased vaccine coverage were absenteeism and consent form return. Vaccine hesitancy is not currently a major issue but remains a potential threat to the program. While Australia's HPV vaccination program is perceived as highly successful, measures to further enhance the program's impact and mitigate potential threats are important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.